Filipa Lynce

dana farber cancer institute

H指数:29

被引数:4,924

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world clinical outcomes of patients with early-stage TNBC and BRCAm who were treated with adjuvant capecitabine in the United States

美国早期TNBC和BRCAm患者接受辅助卡培他滨治疗的实际临床结局

Breast Cancer Research and Treatment

IF3

2026-08-120

OAAI

CLTR-10 PHASE I/II STUDY OF STEREOTACTIC RADIOSURGERY WITH CONCURRENT OLAPARIB FOLLOWED BY ADJUVANT DURVALUMAB AND PHYSICIAN’S CHOICE SYSTEMIC THERAPY IN SUBJECTS WITH BREAST CANCER BRAIN METASTASES (SOLARA)

CLTR-10 I/II期研究：对于乳腺癌脑转移患者，进行立体定向放射手术联合奥拉帕利，随后进行辅助度伐利尤单抗和医生选择系统性治疗的临床研究（SOLARA）

Neuro-Oncology Advances

IF4.1

2026-08-070

Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort

胚系BRCA1/2携带者两组匹配队列的研究结果与治疗模式

JNCI Cancer Spectrum

IF4.1

2026-05-250

Stefania Morganti, MD; Se E Kim, MB; Qingchun Jin, MPH; Jaeyoon Cha, BA; Jacqueline E Zeigler, BS; Alexandra B Newman, MD; Gregory J Kirkner, MPH; Craig Snow, MHA; Yue Zheng, MS; Julie Vincuilla, BS; Tonia Parker, BS; Ryan M Buehler, BA; Brittany L Bychkovsky, MD, MSc; Kate E Dibble, PhD; Tal Sella, MD; Kathryn J Ruddy, MD, MPH; Shoshana M Rosenberg, ScD, MPH; Laura C Collins, MD; Jeffrey Peppercorn, MD, MPH; Lidia Schapira, MD; Virginia F Borges, MD; Yaileen D Guzman-Arocho, MD; Steven E Come, MD; Ellen Warner, MD, MSc; Philip D Poorvu, MD; Matteo Lambertini, MD, PhD; Giuseppe Curigliano, MD, PhD; Melissa E Hughes, MSc; Elizabeth A Mittendorf, MD, PhD, MHCM; Tari A King, MD; Nancy U Lin, MD; Judy E Garber, MD, MPH; Nabihah Tayob, PhD; Sara M Tolaney, MD, MPH; Ann H Partridge, MD, MPH; Filipa Lynce, MD; null

Scientific highlights and perspectives from the International Inflammatory Breast Cancer Symposium 2025

2025年国际炎性乳腺癌研讨会的重要科学成果与展望

Cancer

IF5.1

2026-05-140

PRE

Eleonora Nicolò MD; François Bertucci MD, PhD; Hamouda Boussen MD; Giuseppe Curigliano MD, PhD; Valerie Fraser; Lorenzo Gerratana MD; Savitri Krishnamurthy MD; Huong T. Le-Petross MD; Bora Lim MD; Filipa Lynce MD; Anthony Lucci MD; Serena Lucotti PhD; Maroua Manai PhD; Sofia Merajver MD, PhD; Noémie Missal MSc; Azadeh Nasrazadani MD, PhD; Amr Soliman MD, PhD; Carmine Valenza MD, MPH; Christophe Van Berckelaer MD; Steven Van Laere PhD; Wendy A. Woodward MD, PhD; Massimo Cristofanilli MD; Gayathri Devi PhD, MS

Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/ 6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2-metastatic breast cancer in US routine clinical practice

美国常规临床实践中，HR+/HER2-转移性乳腺癌患者使用CDK4/6抑制剂联合芳香化酶抑制剂的真实世界无进展生存期2（PFS2）和肿瘤缓解情况

Breast

IF7.9

2026-04-010

OAAI

Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer

新辅助派姆单抗联合化疗治疗非转移性三阴性炎性乳腺癌的病理完全缓解

ESMO Open

IF8.3

2026-01-190

OAAI